Actovegin is a biological drug produced from deproteinised hemodialysate of calf serum with over 50 years of history for its clinical use. There have been many in vitro studies to speculate its potential role and mechanism of action in cells; due to the nature of this drug and serum based culture techniques for most in vitro experiments, presumptuous conclusions and claims from these studies on performance enhancement should be cautiously interpreted. There have been well-designed human in vivo studies suggesting Actovegin does not enhance human performance, and has potentially good clinical applications to treat injuries, strokes and diabetes. Recently, evidence has emerged suggesting Actovegin has anti-inflammatory and anti apoptotic effects on injured tissues; further clinical research is needed to define these effects. This site provides a review of Actovegin summarizing outcomes from recent publications.

What is Actovegin?

Actovegin photo

Actovegin (Takeda Pharmaceutical Company Ltd, Osaka, Japan) is a biological drug produced from deproteinised haemodialysate of calf serum with a high standard of quality control.  (figure 1) There are over 50 years of history for its clinical use with much in-vitro as well as clinical evidence to support its efficacy[1]. Indeed, the role of calf blood derivatives have an established role in the maintenance of cellular viability and survival in vitro, for example, it is commonly used in the form of foetal bovine serum (FBS) supplement in tissue culture medium, and the success of many in-vitro experiments is dependent on the batch of FBS employed. Therefore, Actovegin can be viewed as a highly controlled and approved form of FBS with an excellent clinical track record for use in human participants. 

Muscle Injuries - Current Strategies and Issues

The use of Actovegin as an intramuscular injection therapy for acute muscle tears was first documented by Pfister and Koller. They reported a reduction in recovery time from 8.3 weeks to 5.5 weeks in treatment groups.  Since this study there has been limited supporting evidence for its role in the treatment of muscle injuries. Lee et al. have published a study on the effects of standalone Actovegin therapy, reporting a reduction in return to play time in injured, professional footballers of 8 days when compared to physiotherapy alone (p=0.033). read more

Treatment of fresh muscle injury. Pfister A, Koller W. Sportverletz Sportschaden 1990;4:41-44

Our experience on Actovegin, is it cutting edge?  Lee P, Rattenberry A, Connelly S, Nokes L. Int J Sports Med 2011;32:237-241


Actovegin is a biological drug that has been used for the treatment of sports muscle injuries. Several in vitro studies have shed light on potential mechanisms of action and the drug has consistently demonstrated its potential to reduce return from injury time for muscle tears in elite athletes. Yet it was banned for a time under the International Olympic Committee (IOC) as a blood doping agent, this ban was based on presumptuous conclusions and subsequently lifted after no indisputable evidence could be provided. This editorial aims to provide readers with some of the key, objective facts relating to Actovegin and then based on this, will offer an infromed opinion on its role in sports medicine. We also hope to highlight the importance of evidence-based medicine, particularly in the volatile field of Sports Medicine, and the need for facts, not fiction. read more

Actovegin Equals to Performance Enhancing Drug Doping: Fact or Fiction? Lee et al., J Tissue Sci Eng 2016, 7:3 DOI: 10.4172/2157-7552.1000179


Actovegin is not prohibited in sport under the WADA List of Prohibited Substances and Methods except if it is used by intravenous infusion/injection according to section M2 (Chemical and Physical Manipulation) of the List.

Lab based Evidences

coming soon



Link to amazon: click here

© Actosports 2016